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Introduction  
Probiotics are defined as live 
microorganisms which when administered in 
adequate amounts confer a health benefit on 
the host (FAO/WHO, 2002). They are live 
nonpathogenic preparation administered to 
improve and restore the microbial balance of 
gastrointestinal tract. Probiotics, as 
biological factors, control the gut microbiota 
and result in its progression. They are 
organisms which are generally regarded as 
safe (GRAS) and consumed without the risk 
of infections (FAO/WHO, 2002). Most 
organisms used as probiotics belong to the 
lactic acid bacilli, Lactobacillus and 
Bifidobacterium, a nonpathogenic E. coli                                  
strain (E. coli Nissle 1917), Saccharomyces 
boulardii, Clostridium butyricum, and 
Streptococcus salivarius subspecies 
thermophilus, genetically engineered 
bacteria that secrete immunosuppressive 
substances such as interleukin-10 (IL-10) 
have been studied (Sartor, 2004).   
Probiotics are commonly consumed as part 
of fermented foods with specially added 
active live cultures, such as in yogurt, soy 
yogurt, cheese or as dietary supplements. 
Probiotics may beneficially affect the host 
by augmenting its intestinal microbial 
population beyond the amount already 
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existing, thus possibly inhibiting pathogens. 
Specific attributes that position an organism 
to be an effective probiotics include acid 
tolerance, bile tolerance, cell surface 
hydrophobicity, protoplast regeneration, 
antimicrobial activity, cholesterol removal 
and bile salt deconjugation, gut colonization, 
lactose removal, protease and amino 
peptidase activity (Sartor, 2004; Sudah et 
al., 2009; Scaldaferri et al., 2013). To be 
functional in the intestinal tracts, probiotics 
are expected to be viable and in a certain 
number. As such the modes of delivery and 
production should be targeted towards 
maintaining the viability of the organism 
after production and even during storage.   
Probiotic organisms may be naturally 
occurring microbes (as is the case for all 
used in food), or microbes that have been 
genetically altered for a specific effect. The 
complete mechanism of action of probiotics 
in disease management is not known, 
however, the major activity thus appear to 
be via colonization competitive shielding off 
of pathogens and immunomodulations. 
Several research effort have explained these 
mechanism of activities to include 
improving gastrointestinal tract health via 
modifying gut pH, antagonizing pathogens 
through production of antibacterial 
compounds, competitive exclusions of 
pathogens at the binding and receptor sites, 
enhancing the immune system, synthesizing 
and enhancing the bioavailability of 
nutrients, competing for available nutrients, 
reducing the symptoms of lactose 
intolerance, decreasing the prevalence of 
allergy in susceptible individuals, and 
reducing risks of certain cancers through 
binding of deleterious mutagens and 
carcinogens (Hirayama and Rafter 2006; 
Jain et al., 2010).   
In the present review article we highlight 
some of the diseases for which probiotics 
have been used to manage and ameliorate 
conditions with a view to steering interests 
for further probe into specific mechanisms 
of activity of probiotics and its possible use 
in the management of diseases hitherto not 
perceived/conceived. For more in-depth 
view on the diseases highlighted, the reader 
is kindly asked to refer to specific 
publications.  
Probiotics in the treatment/ management 
of diarrheal diseases  
Diarrhea has been defined as the passage of 
3 or more loose or liquid stools per day, or 
more frequently than is normal for the 
individual. It is usually a symptom of 
gastrointestinal infection, which can be 
caused by a variety of bacterial, viral and 
parasitic organisms, diarrhea could also be 
antibiotic associated (WHO, 2013). Diarrhea 
leads to fluid loss, and may be life-
threatening, particularly in young children 
and people who are malnourished or have 
impaired immunity (WHO, 2013). Reports 
abound on the use of probiotics for 
treatment of antibiotic associated diarrhea 
(AAD) and the management of chronic and 
acute enteric infections and their associated 
diarrheal complexes.   
The rationale for using probiotics for 
treatment of diarrhea is based on the 
observation that they act either by modifying 
the composition of colonic microbial flora or 
by modulating the immune response. 
Lemberg et al. (2007) penned that probiotics 
modify the composition of microbial flora 
by several mechanisms which include: 
Competing with pathogens for nutrients and 
receptors; Inducing hydrolysis of toxins and 
receptors; Inducing production  of  
antimicrobial  substances  including  
peptides  of  the  innate immune system; 
Inducing production of organic acids and 
modulation of nitric oxide synthesis. Seth et 
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al. (2008) opined regulating intestinal 
permeability by modulating the epithelial 
tight junctions as a mechanism of action 
while Walker (2008) noted the exerting of a 
tropic action on the intestinal mucosa, which 
leads to brush border enzyme activation, 
stimulation of glucose absorption and anti-
apoptotic effects on the enterocyte as one of 
the action mechanisms of probiotics in the 
management of diarrhea.   
McFarland (2009) submitted that antibiotic 
associated diarrhea (AAD) is a common 
complication of most types of antibiotics, 
especially for broad-spectrum antibiotics 
such as clindamycin, beta-lactams and 3rd 
generation cephalosporins. The non-
selective action of antibiotics perturb the 
normal microbial flora of GIT, which leads 
to overgrowth and multiplication of 
pathogenic microorganisms i.e, Clostridium 
difficle, Clostridium perfringens, 
Staphylococcus aureus, Klebsiella oxytoca, 
Candida spp and Salmonella spp., which 
ultimately result in the production of toxin, 
leading to diarrhea (McFarland, 2009). . 
Perturbation of normal microbial flora leads 
to the decrease in the number of bacteria 
involved in the production of short chain 
fatty acids. These fatty acids are important 
for the nutrition of the enterocyte and for 
water and electrolyte absorption, and their 
decrease may result in watery diarrhea. 
Erythromycin is special case of 
antimicrobial agents which directly 
stimulate the motilin and induce the diarrhea 
(McFarland, 2009).  
Kotowsha et al. (2005) observed that oral 
administration of selected probiotics strain 
along with antibiotics can be the better 
option to handle the situation of 
antimicrobial associated diarrhea. In a 
clinical study, Kotowsha et al. enrolled 269 
children who were taking antibiotics for ear 
or respiratory infections and randomized 
them to either Saccharomyces boulardii 
(500 mg/d) or placebo for the duration of the 
antibiotic treatment. Even though the 
follow-up time was short (two weeks post-
antibiotic), the frequency of diarrhea in the 
probiotic group was significantly less (3.4%) 
compared to 17.3% in the placebo group 
(Kotowsha et al., 2005).  
Clostridium difficile associated diarrhoea 
(CDAD) is most often caused by 
clindamycin,   cephalosporins,   ampicillin,   
and   amoxicillin.   Clostridium   difficile   
has   been associated with symptomatic 
diarrhoea since being identified as the 
pathogen responsible for 
pseudomembranous colitis (Santosa et al., 
2006). Total flora replacement or faecal 
bacterio therapy has been described as an 
effective treatment alternative in severe C. 
difficile infections. It is based on transfer of 
faecal flora from a healthy individual to a 
severely ill patient. Total flora replacement 
has also been used to manage severe 
constipation, irritable bowel syndrome, and 
inflammatory bowel disease. Homologous 
faecal enemas have been used in recalcitrant 
cases of CDAD usually with stool donated 
by the patient s partner. L. acidophilus and 
L. rhamnosus are probiotics that have been 
detected in these fecal samples. It is an 
adjunctive therapy in sporadic clinical use. 
(Borody et al., 2003; 2004).  
Traveler s diarrhea occurs in about half of 
travelers who visit high-risk areas. Although 
most cases are mild and self-limiting, there 
is considerable morbidity.  Antibiotics are 
an effective means of prophylaxis but are 
not recommended for widespread use. 
Hence there is a need for cost-effective 
alternative treatments. The efficacy of 
probiotics in traveler s diarrhea has been 
reported with Saccharomyses boulardii and 
Lactobacillus rhamnosus GG shown to have 
significant effects. S. boulardii seems to 
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prevent bacterial diarrhoea more effectively, 
while Lactobacillus rhamnosus GG has been 
shown to be more effective against viral and 
idiopathic diarrhea (Goldin and Gorbach, 
2008).  
Infective diarrhea due to Rotavirus is the 
leading cause of infantile diarrhea 
worldwide and rapid oral rehydration is the 
primary treatment.  Several  potential  
mechanisms  have  been  proposed  for  how 
lactobacilli reduce the duration of rotavirus 
diarrhea through competitive blockage of 
receptor sites in which lactobacilli bind to 
receptors, enhanced immune response, and 
signal(s) from lactobacilli that regulates the 
secretary and motility defenses designed to 
remove perceived noxious substances and 
lactobacilli that produce substances meant to 
inactivate the viral particles. The probiotics 
most frequently studied for treating acute 
diarrhea include Lactobacillus rhamnosus 
GG and Lactobacillus reuteri (Santosa et al., 
2006, Goldin and Gorbach, 2008).  
Probiotics in inflammatory bowel disease 
(IBD)  
Inflammatory bowel disease (IBD) is a 
collective term, used for ulcerative colitis 
(UC),  Crohn s disease (CD) and Pouchitis. 
IBD is an abnormal immune response 
against luminal antigen of commensal 
bacteria in genetically predisposed 
individuals (Sartor, 2004; Fedorak et al., 
2004; Gionchetti et al., 2005; Marteau et al., 
2009). Traditionally known medication used 
in IBD includes 5-aminosalicylic acid (5-
ASA) and corticosteroids. Limited clinical 
trials suggest that selected probiotics 
species, alone or in combination, can 
prevent recurrent intestinal inflammation 
and possibly treat active IBD, with best 
results in pouchitis, and, to a lesser extent, 
ulcerative colitis and Crohn s disease (Table 
1 adapted from Sartor, 2004). 
Several probiotics mechanisms of action, 
relative to inflammatory bowel disease, have 
been elucidated: (1) competitive exclusion, 
whereby probiotics compete with microbial 
pathogens i. e. colonization resistance- 
occupy ecologic niche. ; (2) 
immunomodulation and/or stimulation of an 
immune response. Alter immunoregulation 
by induce IL-10, transforming growth factor 
expression and secretion, stimulate secretory 
immunoglobulin A production, decrease 
tumor necrosis factor expression ; (3) 
antimicrobial activity and suppression of 
pathogen growth, inhibit pathogenic enteric 
bacteria via decrease luminal pH,  secrete 
bacteriocidal proteins,; (4) enhancement of 
barrier activity. Improve epithelial and 
mucosal barrier function, (Produce short 
chain fatty acids, including butyrate. 
Enhance mucus production and increase 
barrier integrity; and (5) induction of T cell 
apoptosis, block epithelial binding
induction of MUC 2 inhibit epithelial 
invasion (Rioux and Fedorak, 2006; Marteau 
et al., 2009; Scaldaferri et al., 2013).  
Fujmori et al.(1997) reported that in Crohn s 
disease, commensal E. coli strain stimulates 
the release of tumor necrosis factor  
(TNF-  )  and  interleukin-8  (IL-8)  by  
inflamed  mucosa.  However, some 
lactobacilli strains including L. casei down 
regulate the spontaneous releases of TNF-  
and the inflammatory response induced by 
E.coli. Therefore, it makes sense either to 
eliminate some bacteria with antibiotics or 
to alter the gut flora, in favor of more 
beneficial bacteria, by the use of   probiotics   
and   prebiotics   (prebiotics   are   dietary   
substances   usually   non-digested 
carbohydrates that  stimulate the growth and 
metabolism of protective commensal enteric 
bacteria) (Fujmori et al., 1997; Scaldaferri et 
al., 2013).    
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Table.1 Randomized Double-Blind Trials of Probiotic Agents in IBD  
Author (date)  Probiotic Clinical situation Result 
Crohn s disease 
Plein, Hotz 
(1993)135   
Saccharomyces 
boulardii 
Maintenance of 
remission 
   diarrhea vs. placebo 
Malchow (1997)93 E. coli Nissle 
1917 
Maintenance of 
remission 
    relapse vs. placebo 
Guslandi (2000)136  
S. boulardii 
Maintenance of 
remission (probiotic  
mesalamine vs. 
mesalamine alone) 
    relapse vs. 
mesalamine 
    alone 
Prantera (2002)94 Lactobacillus GG Postoperative 
prevention 
No benefit 
Ulcerative colitis 
Kruis (1997)85 E. coli Nissle 
1917 
Maintain remission Equal to mesalamine 
(1.6 g) 
Rembacken (1999)86 E. coli Nissle 
1917 
Maintain remission Equal to mesalamine 
Kruis (2001)87 E. coli Nissle 
1917 
Maintain remission Equal to mesalamine 
Ishikawa (2003)88 Bifidobacteria-
fermented milk 
Maintain remission Superior to placebo 
Pouchitis 
Gionchetti (2000)77 VSL#3 Maintain remission 
chronic pouchitis 
Superior to placebo 
Mimura (2002)83  
VSL#3 
Maintain remission 
chronic pouchitis 
Superior to placebo 
Gionchetti (2003)84 VSL#3 Prevention after 
ileostomy closure 
Superior to placebo 
The proposed mechanisms of action of 
probiotics in the management of Crohn s 
disease include changes in short chain fatty 
acids (SCFA) production patterns; reduction 
in pro-inflammatory cytokine secretion, 
improving Th1/Th2 ratios; Eliminating 
pathogens; enhancement of barrier function 
(Fujmori et al., 1997).  
In a study by Malchow, 28 patients of active 
CD were treated with a tapering dose of 
prednisolone and either placebo or E. coli 
Nissle (E. coli Nissle is a nonpathogenic E. 
coli, which colonize the intestine and 
inhibits the growth of enteropathogenic and   
other enteric bacteria. It is proposed that this 
organism, by suppressing enteropathogenic 
bacteria, may have a long-term effect to 
suppress remission). The E. coli Nissle was 
given in an increasing dosage over 24 days 
to the final dose of 5x1010 bacteria per day 
for a year. The patients are assessed for the 
remission .There was higher relapse rate in 
the placebo group (63.6%) as compared to 
the E. coli group (33.3%) (Malchow, 1997).  
Fujimori et al.(1997) treated 10 patients of 
Chorn s disease not responding to 5-ASA 
and prednisolne therapy with a synbiotic 
therapy, (Probiotic - Bifidobacterium and 
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Lactobacillus and Prebiotic- psyllium), for 
12 months. Six patients went into remission, 
one had a partial response with improvement 
of the number bowel movements, and three 
patients were non-responders. There was no 
significant difference between C-reactive 
protein (CRP) and erythrocyte sedimentation 
rate (ESR) values were observed before and 
after the therapy (Fujimori et al., 1997). 
In ulcerative colitis (UC), the composition 
of microflora is imbalanced associated with 
increased number of pro-inflammatory 
bacteria, including Enterobacteriaceae, and 
Bacteroides fragilis and decreased count of 
protective bacteria, including lactobacilli 
and bifidobacteria. Furrie et al. (2005) 
documented the management of ulcerative 
colitis via probiotics. In a double blind study 
for patients with active UC, employing a 
combination of probiotics strain, 
Bifidobacterium longum, with a prebiotic 
composed of an inulin-oligofructose (growth 
substrate) on 18 patients. Nine patients 
assigned to the treatment group and nine to 
the placebo group. Patients assessed with a 
clinical activity index, level of gut 
inflammatory markers and histological sore. 
The patients were treated with the synbiotic 
mixture (probiotics- prebiotic) of placebo 
twice-daily for 4 weeks. At the end of the 
month, the patients were reassessed. The 
patients receiving the synbiotic mixture 
exhibited reduced mucosal inflammatory 
markers in colonic biopsies. There was an 
improvement microscopically .There is 
significant reduction in TNF- and IL- 
levels in mucosal biopsies in patients treated  
with the active therapy as compared to 
placebo (Furrie et al., 2005).  
Pouchitis is an idiopathic inflammatory 
disease of the ileal pouch that occurs in 15% 
53% of patients who undergo total 
abdominal colectomy with ileal pouch-anal 
anastomosis (IPAA) for ulcerative colitis.  
Fecal  stasis  with  immunologic  reactivity  
appears  to  be  important  in  the 
pathogenesis of this disease (Tursi et al., 
2004). Welters et al. (2002) and Kim and 
Hans (2004) demonstrated that using the 
dietary fiber Inulin (24 g/day), for the short 
period of 3 weeks significantly decreases the 
pouchitis as measured by endoscopic and 
histologic score. The results correlated with 
a significant alteration of fecal pH, fecal 
butyrate, and secondary bile acid 
concentration.  
In a randomized, double-blind, placebo-
controlled study 40 patients were 
randomized within a week after surgery to 
receive either VSL#3 (3 g, 9 x 1011 
bacteria/day) or placebo for 12 months 
(Welters et al., 2002). Two of 20 (10%) of 
the patients treated with VSL#3 developed 
an episode of acute pouchitis compared to 
8/20 patients (40%) in the placebo group (P 
< 0.01). Patients treated with VSL#3 and no 
signs of pouchitis had a median stool 
frequency of 5 (range, 3 9) at the end of the 
trial compared to 8 (range, 6 12) in the 
placebo group (with no signs of pouchitis; P 
< 0.001) (Welters et al., 2002).  
Probiotics in Genitourinary tract 
infection  
The genital tract of premenopausal woman 
mainly composed of Lactobacilli, especially 
Lactobacillus crispatus and Lactobacillus 
iners. These lactobacilli engaged in the 
production of bacteriocins, lactic acid and 
hydrogen peroxide, which maintain the pH 
acidic and keep away the pathogenic 
colonies from proliferating.  Imbalanced 
microbial flora offer an opportunity for the 
proliferation of pathogenic microorganism 
such as E. coli, Gardnerella  vaginalis,  
Bacteroides  sp,  beta-Streptococci  ,  
Mobiluncus or    Falcivibrio  spp. and 
Candida albicans (Hillier et al., 1993; Cauci 
et al., 2003; Anukam et al., 2006a.b). 
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Unnecessary receive of broad-spectrum 
antibiotic (excreted out from urine), disrupt 
normal flora, and causes symptomatic 
urinary tract infections such as bacterial 
vaginosis and candidal vulvovaginitis 
((Cauci et al., 2003) Restoring the normal 
flora with lactobacilli may help to treat these 
genital infection.  
The treatment of UTI usually is with oral 
antimicrobial regimens of clindamycin, 
metronidazole or nofloxacin for bacterial 
vaginitis and fluconazole for candidal 
vaginitis. Nevertheless, their nonselective 
antimicrobial action decrease the lactobacilli 
count, and alter the pH (shift to alkaline), 
which ultimately associated with recurrence 
of the infection. Use of effective probiotics 
could be the best option to manage the 
above condition and to break the cycle of 
recurrence.  
In a clinical study conducted on 28 women 
suffering from recurrent candidal 
vulvovaginitis, Hilton et al. (1992) reported 
that administration of vaginal suppositories 
cantaining Lactobacillus rhamnosus GG 
twice daily for seven days, all of the women 
reported an improvement in vaginal 
symptoms and reduction in vaginal 
erythema and discharge.  
Studies have shown that women with 
bacterial vaginosis (no lactobacilli) are at 
significantly increased risk of HIV (Falagas 
et al., 2006; Anukam et al., 2006a,b).The 
prevention or resolution of bacterial 
vaginosis is particularly important in women 
at risk of human immunodeficiency virus 
(HIV) infection. Thus, treatment of bacterial 
vaginosis and promotion of vaginal 
lactobacilli may reduce a woman's risk of 
acquiring HIV-1, gonorrhea, and 
trichomoniasis. A recent publication has 
shown that a human vaginal  probiotic  
strain  (Lactobacillus  reuteri  RC-14)  can  
express  potent  functional  viral inhibitors 
which may potentially lower the sexual 
transmission of HIV (Liu et al., 2006).  
A study constituting 13 women showed that 
consumption of yogurt containing L. 
acidophilus decreased the incidence of C. 
albicans yeast infections (Klebanoff et al., 
1991). Hydrogen peroxide production is a 
key factor in resisting BV disease 
(Klebanoff et al., 1991). Hydrogen peroxide 
producing strains of lactobacilli have been 
found in 6l% of pregnant women with 
normal flora and in only 5% of women with 
BV. Hydrogen peroxide has been shown to 
be toxic to BV causing organisms, namely, 
Gardnerella vaginalis and Prevotella bivia 
(Hillier et al., 1993). Comparable results 
were obtained in open and placebo 
controlled studies in which lyophilized L. 
acidophilus was applied locally or L. 
acidophilus yogurt was given orally (Parent 
et al., 1996, Hallén et al., 1992).    
In these studies, success rates for control of 
BV or Candida vaginitis ranged from 57% 
to 87% in the probiotic group and from 0 to 
22% in the control group (Hallén et al., 
1992). Various molecular methods have 
shown L. crispatus and L. johnsonii to be 
the most common vaginal isolates from 
normal women of child- bearing age (Reid 
et al., 1996) The administration of L. 
rhamnosus GR-l in combination with L. 
fermentum B-54 and RC-l4 by mouth and 
intravaginally has been shown to be safe and 
to reduce the risk of UTIs, BV, and yeast 
vaginitis (Reid et al., 1996).  As with uro- 
genital pathogens, lactobacilli ascend from 
the rectum into the vagina and subsequently 
alter the microenvironment and potentially 
modulate the immunologic status of the host 
such that a normal vaginal flora is more 
often restored and retained (Gardiner et al., 
2002, Cadieux et al., 2002). 
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Probiotics in Hypercholesterolemia and 
Hypertension  
Cholesterol is a precursor to certain 
hormones and vitamins and is a component 
of cell membranes and nerve cells. 
However, elevated levels of total blood 
cholesterol (Hypercholesterolemia) or other 
blood lipids are considered to be a high risk 
factor for coronary heart disease one of the 
leading causes of death. Different 
mechanisms by which probiotics 
preparations could control blood cholesterol 
level have been proposed to include 
assimilation of cholesterol in the small 
intestine by probiotics and incorporation of 
cholesterol into the cell membrane of 
probiotics (Noh et al., 1997; Taranto et al., 
1999;2000; Liong and Shah, 2005a).The 
cholesterol-lowering effect of lactic acid 
bacteria (Streptococcus, Lactobacillus, and 
Bifidobacterium) is well established 
(Nguyen et al., 2007). It has been found that 
the isolated lactic acid bacteria had an 
excellent hypocholesterolemic effect. Some 
strains of lactobacilli have been found to 
remove cholesterol via various mechanisms 
and can be used as a dietary adjunct to lower 
serum cholesterol in vivo (Liong and Shah., 
2005b).     
L. acidophilus deconjugates bile acids into 
free acids that are rapidly excreted from the 
intestinal tract. Because free bile salts are 
excreted from the body, the synthesis of new 
bile acids from cholesterol lowers its 
concentration in the body. Further, it has 
been suggested by Andersson et al.( 1995), 
that the bile flow is stimulated by regular 
milk consumption (l L/day). Isolates of L. 
acidophilus from human intestine are better 
able to assimilate cholesterol and actively 
deconjugate bile salts than commercially 
used cultures of L. acidophilus. 
Lactobacillus plantarum PH04 and L. 
reuteri showed cholesterol-lowering 
activities (De Smet et al., 1998; Nguyen et 
al., 2007).  Clinical investigation have 
suggested a decrease in serum cholesterol 
concentrations during consumption of very 
large amounts (8 L/day) of yogurt or 
fermented milk per day (Hepner et al., 1979) 
Hypercholesterolemia is one of the major 
causes for hypertension (Liong and Shah, 
2005b).   
Probiotics have potential to regulate blood 
cholesterol level in hypercholesterolemia. 
The elevation of blood pressure is found to 
be greatly induced when total cholesterol 
level exceeds 6.4 mmol/L. This may 
increase cardiac output and peripheral 
vascular resistance that causes an elevated 
blood pressure (Noh et al., 1997; Taranto et 
al., 1999; Liong and Shah, 2005b). 
Therefore, lipid metabolism disorders are 
often the causes of hypertension. A variety 
of in vitro experiments and in vivo trials 
have provided experimental evidence to 
support the roles of probiotics in lowering 
serum cholesterol and improving lipid 
profiles, which subsequently leads to a 
reduced risk of hypertension (Noh et al., 
1997; Taranto et al., 1999; Liong and Shah, 
2005b).   
Probiotics in oral and dental diseases  
The application of probiotics in the 
management of dental caries (Meurman  et 
al., 1995; Näse et al., 2001; Ahola  et al., 
2002;  Kang  et al., 2005;  Stamatova et al., 
2007; Caglar et al., 2006; 2007; 2008a,b; 
Cildir et al., 2009), periodontal diseases 
(Grudianov et al., 2002; Volozhin et al., 
2004;), halitosis (Kazor et al.,2003; Burton 
et al., 2006; Kang et al., 2006 ) and oral 
candidiasis (Elahi et al., 2005; Hatakka et 
al.,2007)have been reported.   
The proposed mechanisms of action of 
probiotics might be due to the competition 
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for binding sites in oral biofilms, 
strengthening the mucosal barrier via tropic 
effects on the epithelium, and stimulating 
both the innate and adaptive immune 
system. The ability of probiotics in the 
reduction of S. mutans and other oral 
streptococci with cariogenic potential 
abound.(Meurman et al., 1995; Kang et al., 
2005; Stamatova et al., 2007; Caglar et al., 
2008a, b; Çaglar et al., 2007; Çaglar et al., 
2006; Cildir et al., 2009.)   
A randomized, double-blind, placebo-
controlled intervention study examined the 
effect of milk containing L. rhamnosus GG 
on caries and the risk of caries in children 
when compared with normal milk (Näse et 
al., 2001), probiotic milk was able to reduce 
S. mutans counts at the end of the trial and a 
significant reduction of caries risk was also 
observed. The putative caries prophylactic 
effect of probiotics has been also confirmed 
by daily intake of cheese containing L. 
rhamnosus GG and L. rhamnosus LC 
705(Ahola et al., 2002). The probiotic 
cheese significantly reduced S. mutans 
counts in the intervention group during the 
post-treatment period when compared with 
the controls. Another probiotic species, 
Bifidobacterium DN-173 010, ingested once 
daily with yogurt demonstrated a significant 
reduction of salivary S. mutans, whereas no 
significant reduction was found in 
lactobacilli levels (Çaglar et al., 2005).  
Periodontal inflammation has been reduced 
and also positively affected by the 
administration of two probiotic tablet forms 
Bifidum bacteria and lactic acid bacteria 
available on the Russian market (Grudianov 
et al., 2002). Studies have also shown that a 
periodontal dressing containing L. casei can 
reduce the number of most common 
periodontal pathogens and extend remission 
up to 10 12 months (Volozhin et al., 2004).  
Bad breath in the oral cavity ( Halitosis or  
foetor ex ore} is mainly ascribed to the 
production of volatile sulfur compounds 
(VSC) predominantly by Gram negative 
anaerobes residing in periodontal pockets 
and on the tongue dorsum. The replacement 
of bacteria implicated in halitosis by 
colonization with probiotic bacterial strains 
from the indigenous oral microbiota of 
healthy humans may have potential 
application as adjuncts for the prevention 
and treatment of halitosis. Kazor et al. 
(2003) reported that L. salivarius was the 
most predominant species detected in 
healthy subjects, whereas it was detected in 
only one of the subjects with halitosis at 
very low levels .The rationale of probiotic 
implementation in cases of halitosis has 
been documented in several studies. S. 
salivarius K12 taken in a lozenge after a 
mouthwash could reduce oral VSC levels in 
85% of the subjects in the test group (Burton 
et al., 2005). Weissela cibaria was also 
reported to being able to reduce VSC 
production both in vitro and in vivo (Kang et 
al.,2006a). A contributing factor to malodor 
reduction can be the ability of W. cibaria to 
co-aggregate with species renowned for 
their VSC production (F. nucleatum, for 
example), thus reducing the source for 
malodorous compounds in the oral cavity 
(Kang et al.,2006b).   
Hatakka et al.(2007) reported that probiotic 
applications in the oral cavity have the 
potential to alleviate symptoms and reduce 
pathogenic potential of Candida species. 
They observed that a 16-week probiotic 
intervention study demonstrated a 
significant reduction by 75% of high yeast 
counts in the elderly and Hyposalivation 
reduction was also observed by the intake of 
L. rhamnosus GG containing cheese 
associated with control of oral Candida.   
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Elahi et al.(2005), Wagner et al.(2000) in 
vivo studies on mice have shown that 
lactobacilli might indeed be effective in 
controlling oral candidiasis. A higher 
clearance of C.albicans in mice fed with L. 
acidophilus compared to control group was 
demonstrated, however, no noticeable delay 
in colonization of the oral cavity by C. 
albicans of immunocompromized mice was 
achieved when heat killed L. casei and L. 
acidophilus cells were given   
Stamatova and Meurman, (2009) in 
randomized controlled trials have 
nevertheless shown that probiotics may 
control dental caries in children due to their 
inhibitory action against cariogenic 
streptococci. They observed that less 
evidence exists on their role in periodontal 
disease or oral yeast infections.   
Probiotics in Kidney diseases  
The number of patients with chronic kidney 
disease (CKD) is rising worldwide and it is 
now being recognized as a major public 
health concern. Natarajan et al. (2009; 2010) 
observed oral administration of a probiotic 
formulation of selected microbial strains 
extend renoprotection via intraintestinal 
extraction of toxic waste solutes in patients 
with chronic kidney disease (CKD). The 
main outcomes of this investigation include 
a significant reduction of BUN (blood urea 
nitrogen, serum creatinine, and uric acid.), 
enhanced well-being, and absence of serious 
adverse effects (Natarajan et a.l., 2010), thus 
supporting the use of the chosen probiotic 
formulation for bowel-based toxic solute 
extraction.   
Lieske et al.(2005), Hoesl and 
Altwein,(2005) noted that a probiotic 
preparation able to degrade oxalate in vitro 
was shown to reduce oxalate fecal excretion. 
A high level of oxalate in the urine is a risk 
factor for development of kidney stones.  
Several probiotics preparations induce 
protective cytokines, including IL-10, and 
suppress proinflammatory cytokines, such as 
TNF- and IL-6. Intestinal microflora is 
deranged in hemodialysis (HD) patients as 
an increase in aerobic bacteria such as E. 
coli and a decrease in anaerobic bacteria 
such as Bifidobacterium. One study reported 
that oral administration of Bifidobacterium 
longum in a gastroresistant seamless capsule 
decreases the the pre-HD serum levels of 
homocysteine and indoxyl sulfate. It has 
also been shown that synbiotics containing 
lactobacilli can reduce serum level of p-
Cresol in HD patients. High-serum p-cresyl 
sulfate and indoxyl sulfate levels were 
associated with renal progression. Serum 
concentrations of p-cresol are independently 
associated with overall mortality and 
cardiovascular disease in HD patients.   
In-vitro and in-vivo investigations 
undertaken by Kibow Biotech (2012) 
suggest that oral administration of a 
probiotic formulation comprised of selected 
microbial strains may extend renoprotection 
via intra intestinal extraction of toxic solutes 
in patients with CKD stages 3 and 4. They 
opined that science has defined more than 
100 uremic toxins that may be involved in 
Chronic Kidney Disease and as well in CKD 
Stage 5, also known as end-stage renal 
disease (ESRD), and that certain probiotic 
microorganisms can utilize urea, uric acid 
and creatinine and other toxins as its 
nutrients for growth. Overloaded and 
impaired kidneys have a buildup of these 
poisonous wastes in the bloodstream, 
probiotics microorganisms multiply, thereby 
creating a greater diffusion of these uremic 
toxins from the circulating blood across the 
lining of the intestinal walls into the bowel. 
This increased microbial growth is excreted 
along with the feces (which is normally 50% 
microbes by weight) (Kibow Biotech, 2012)  
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Probiotics in Chronic fatigue syndrome 
(CFS)  
CFS is a medically unexplained illness, 
characterized by persistent and relapsing 
fatigue, in addition to cognitive dysfunction, 
headaches, joint pains, and central nervous 
system disturbances (Komaroff et al., 1996). 
Aaron et al.( 2000) observed that many CFS 
patients also complain of gastrointestinal 
(GI) disturbances and are more likely to 
report a previous diagnosis of irritable bowel 
syndrome (IBS), meet diagnostic criteria for 
IBS and experience IBS related symptoms.  
Whitehead et al. (2002) noted that while 
CFS is neither a gastrointestinal nor 
psychiatric disorder per se, over 50 percent 
of patients with CFS meet the diagnostic 
criteria of IBS, and anxiety itself is often a 
hallmark symptom in those with IBS. This 
corroborate the discovery that gut pathogens 
in the GI tract can communicate with the 
central nervous system and influence 
behavior associated with emotion, anxiety in 
particular, even at extremely low levels and 
in the absence of an immune response (Lyte 
et al., 1998; Goehler et al., 2007).   
Probiotics, or live microorganisms which 
confer a health benefit on the host, have the 
potential to influence mood-regulating 
systemic inflammatory cytokines, decrease 
oxidative stress and improve nutritional 
status when orally consumed (Logan et al., 
2003). Several researches indicate that there 
are marked alterations in the intestinal 
microflora of CFS patients, including a 
lowered level of bifidobacteria and small 
intestinal bacterial overgrowth (Butt et al., 
1998; Logan et al., 2003; Rao et al. 2009) It 
has been observed that the oral 
administration of Lactobacillus casei strain 
Shirota (LcS) caused a significant rise in 
fecal Bifidobacteria spp and Lactobacillus 
spp in CFS and the administration of 
Lactobacillus casei strain Shirota (LcS) or 
placebo to otherwise healthy adults, reveals 
probiotics helped for mood regulation. 
Those with the lowest scores in the 
depressed/elated dimension at baseline had 
significant improvement in mood scores 
after taking the probiotic compared to the 
placebo group. The probiotic bacteria and 
placebo were unable to make a difference in 
those with the highest baseline mood scores 
(Benton et al., 2007; Rao et al., 2009). In a 
similar study using the animal model of 
depression, the oral administration of a 
probiotics was shown to increase plasma 
tryptophan levels, decrease serotonin 
metabolite concentrations in the frontal 
cortext and dopamine metabolite 
concentrations in the amygdaloid cortex 
(Desbonnet et al., 2008).   
Probiotics in Diabetes  
Diabetes mellitus has been described as a 
metabolic disease associated with a series of 
multiple risk factors that can be effectively 
managed by multifactorial interventions 
including dietary manipulations. Several 
research findings (Esteve et al., 2011; 
Kootte et al., 2012; Panwar et al., 2013; 
Stachowicz and Kiersztan,2013),  observed 
that in addition to risk factors such as 
genetic predisposition, epigenetic changes 
and unhealthy lifestyle, altered gut 
microbiota is a major risk factor because it 
cause increased adiposity, -cell 
dysfunction, hyperglycemia, 
hypercholesterolemia, dyslipidaemia, 
metabolic endotoxemia, systemic 
inflammation, intestinal permeability (leaky 
gut), defective secretion of incretins and 
oxidative stress associated with type 2 
diabetes (T2D). It is also a major risk factor 
in type 1 diabetes (Calcinaro et al., 2005).  
The influence of gut microbiota on health 
and disease has been established (Ulisse et 
al., 2001; Schultz et al., 2002; Vaarala, 
2003; Sing et al.,2009), results from several 
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genomic, metagenomic and metabolomic 
studies have provided substantial 
information to target gut microbiota by 
dietary interventions for the management of 
T2D (Panwar et al., 2013). Probiotics 
particularly lactobacilli and bifidobacteria 
have emerged as the prospective 
biotherapeutics with proven efficacy to 
abrogate progression and development of 
diabetes through improving the altered gut 
microbial composition and by targeting all 
the possible risk factors.  
Calcinaro et al. (2005) reported that orally 
administered probiotic compound VSL#3 (a 
probiotic compound containing 3×1011/g 
viable lyophilised bacteria, including 
bifidobacteria (B. longum, B. infantis and B. 
breve), lactobacilli (L. acidophilus, L. casei, 
L. delbrueckii subsp. L. bulgaricus and L. 
plantarum) and Streptococcus salivarius 
subsp. thermophilus.) prevented 
autoimmune diabetes and induces 
immunomodulation by a reduction in 
insulitis severity in a mice. They opined that 
the results provide a sound rationale for 
future clinical trials of the primary 
prevention of type 1 diabetes in man by oral 
VSL#3 administration. Similarly, Matsuzaki 
et al.(1997) reported that oral administration 
of heat killed Lactobacillus casei to non-
obese diabetic (NOD) mice reduces the 
incidence of diabetes, but the mechanism 
underlying this finding has not been 
elucidated.   
The consumption of probiotics was reported 
to prevent or delay the onset of diabetes and 
subsequently reducing the incident of 
hypertension. In a study conducted by 
Yadav et al. (2007), it was found that the 
administration of Dahi (an Indian fermented 
milk product) containing Lactobacillus 
acidophilus, L. casei and L. lactis to high 
fructose-induced diabetic rats for eight 
weeks decreased the accumulation of 
glycogen in the liver of rats compared to the 
control that was not fed the probiotics. High 
fructose diets induce type II diabetes that is 
associated with insulin resistance, 
hyperinsulinemia, hypertriglyceridemia and 
hypertension. This caused by the 
mobilization and accumulation of fructose in 
the liver that increases the rate of 
lipogenesis and synthesis of triacylglycerol. 
The probiotic dahi-supplemented diet 
significantly delayed the onset of glucose 
intolerance, hyperglycemia, 
hyperinsulinemia, dyslipidemia, and 
oxidative stress in high fructose-induced 
diabetic rats, indicating a lower risk of 
diabetes and its complications. The 
catabolism of fructose ultimately induces 
insulin resistance (Yadav et al., 2007). 
Similarly, Eitahed et al (2011) reported that 
probiotic yogurt improved total cholesterol 
and LDL-C concentrations in type 2 diabetic 
people and may contribute to the 
improvement of cardiovascular disease risk 
factors.  
The beneficial effects of co-consumption of 
probiotics with diabetic drugs on controlling 
diabetes have been reported. Gliclazide is an 
oral anti-diabetic sulfonylurea drug that has 
beneficial extra pancreatic effects when 
insulin therapy is insufficient. Such  
findings,  point  toward  the  beneficial  
effects  of  probiotics  for  treating diabetes 
in synergism with other diabetes drug and 
thereby reduces the incidence of diabetes 
related hypertension. Amar et al. (2011), 
Cani et al. (2007) reported that dietary 
modulation of gut microbiota with a view to 
increasing bifidobacteria reduced 
endotoxaemia and improved glucose 
tolerance and insulin secretion, as well as 
reducing inflammation development in high 
fat-diet-fed mice. Together, these findings 
suggest that the gut microbiota contribute to 
the pathophysiological regulation of 
endotoxaemia and set the tone of 
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inflammation, glucose tolerance and insulin 
secretion. Thus, specific strategies for 
modifying gut microbiota in favour of 
bifidobacteria could be useful tools for 
reducing the impact of high-fat feeding on 
the occurrence of metabolic diseases.  
Probiotics in Cancer  
Cancer is a complex disorder, characterized 
by the uncontrolled growth and spread of 
abnormal cells. There is not yet a cure for 
cancer largely because the exact causes of 
most types of cancer are still not known but 
however, it is a combination of various 
metabolic and physiologic disturbances in 
the cell, which are directly or indirectly 
related to the involvement of genetic 
makeup (Giovannucci, 2007; Jain et al., 
2010;  ). It has been reported that diet makes 
an important contribution to cancer, e.g., up 
to 75% of colorectal cancer cases are 
thought to be associated with diet, implying 
that risks of cancer are potentially reducible. 
Evidence from a wide range of sources 
supports the view that the colonic microflora 
is involved in the etiology of cancer 
(Hirayama and Rafter, 2006). This has led to 
intense interest in factors such as probiotics 
that can modulate gut microflora and its 
metabolism.  
 It is known that the risk of developing many 
types of cancer can be reduced by adopting 
certain lifestyle changes, such as quitting 
smoking and eating a nutritional balanced 
diet. The environment delivers risk factors 
that cause mutations and initiate cancer or 
enhance growth by genetic and epigenetic 
mechanisms (Ferguson, 1999). Nutrition 
may supply products that may counteract the 
causative factors (Johnson et al., 1994) and 
that can be recommended on the basis of a 
wholesome and complete diet (Pool-Zabel, 
2005). Much attention has focused on 
decreasing cancer risk through diet 
alterations, particularly consumption of 
probiotics and increasing intake of dietary 
fiber (prebiotics). Several case control 
studies of cancer has reported inverse 
association for yogurt, cultured milk and 
other fermented milk (Le et al., 1986; 
Young and Wolf, 1988; Veer et al., 1989; 
Peters et al., 1992; Boutron et al., 1996;). 
However, Kampman et al. (1994a, b) 
reported a weak non significant inverse 
association for fermented dairy products and 
colorectal cancer and no association for 
intake of dairy products and decreased risk 
of colon cancer. Reports abound on 
reduction of mutagenic activity by L. 
acidophilus, L. casei and Bifidobacterium 
bifidum cultures (Biasco et al., 1991; 
Lidbeck et al., 1992; Aso and Akaza 1992; 
Hayatsu and Hayatsu, 1993; Aso et al., 
1995)  
It has been reported that ingestion of 
probiotics, prebiotics, or combinations of 
both (synbiotics) plays an important role in 
the prevention of colorectal cancer (Jain et 
al., 2010). Goldin and Gorbach have 
demonstrated that dietary administration of 
some specific lactobacilli strains 
significantly decreased the incidence of 1, 2-
dimethylhydrazine-induced experimental 
colon cancer (Goldin et al., 1996; Goldin 
and Gorbach, 2008). The microbial flora and 
the immune system of the body play an 
important role in the modulation of 
carcinogenesis. Both may be influenced by 
the probiotics. The overall mechanism of 
probiotic action in the regulation of cancer is 
not known, however, some of the deduced 
mechanisms (Hirayama and Rafter, 2006; 
Jain et al., 2010) include:  
Decreasing the exposure of microbial 
flora to chemical carcinogens 
Detoxifying ingested carcinogens,/ 
inhibition of carcinogens and/or 
procarcinogens 
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Decreasing  the  population  or  
metabolic  activity  of  bacteria  that  
may  generate carcinogenic 
compounds ie inhibition of bacteria 
that convert pro- carcinogens to 
carcinogens 
Producing compounds that inhibit 
the growth of tumor cells 
Stimulating the immune system to 
defend better against cancer cell 
proliferation 
Producing metabolic products (e.g. 
butyrate) which improve 
programmed cell death (apoptosis). 
reduction of intestinal pH to reduce 
microbial activity 
alteration of colonic motility and 
transit time.  
The preventions or delay in development of 
intestinal tumors by lactobacilli is ascribed 
to its binding to mutagenic compounds in 
the intestine and suppressing the growth of 
causative bacteria, which convert 
procarcinogens into carcinogens. The ability 
of lactobacilli to reduce the risk of cancers 
has also been based on their ability to 
modify gut microflora and to decrease B-
glucoronidase and other carcinogen levels 
(Hirayama and Rafter, 2006; Jain et al., 
2010).  Reddy et al. (1997) developed 
azoxymethane-induced aberrant crypt foci in 
colon of rats and found that a stimulated 
growth of bifidobacteria in the colon could 
lead to the inhibition of colon 
carcinogenesis. The authors suggested pH-
lowering effect of bifidobacteria in the 
colon, which subsequently inhibited the 
growth of E. coli and clostridia.   
A decrease in growth of such pathogenic 
microorganisms may also produce the 
modulation of bacterial enzymes   such   as   
beta-glucuronidase that   can   convert   pro-
carcinogens   to   proximate carcinogens. 
There has been evidence that some 
probiotics produce butyric acid and that this 
molecule can influence the rate of apoptosis 
in enterocytes. Probiotics also neutralize the 
activity of mutagens such as 4-
nitroquinoline-N-oxide, 2-nitrofluorene, and 
benzopyrene (Wollowski et al., 2001). Some 
probiotics may decrease the fecal 
concentration of enzymes, mutagens, and 
secondary bile salts that may be involved in 
colon carcinogenesis. L. casei Shirota strain 
is reported to possess promising potential for 
cancer chemoprevention (Morotomi, 1996). 
L. rhamnosus GG can protect against the 
formation of dimethylhydrazine-induced 
colon cancer in rats (Goldin et al., 1996).  
Conclusion  
Various in vitro, animal model and case 
control studies proved the potential for and 
prebiotics to exert therapeutic effects. 
Certain combinations of pro- and prebiotics 
(synbiotics) have revealed greater efficacy  
than either treatment alone, although there 
is, however, few randomized controlled 
clinical trials and epidemiological studies 
demonstrating the anti-disease effects of 
probiotics in human, ie studies in humans 
have been less definitive, the few clinical 
studies do provide evidences that dietary 
probiotics interact with the host and possibly 
with the intestinal microbiota and dietary 
content to exert protective effects in the 
etiology of some diseases. Great care must 
be exercised in extrapolating the results of in 
vitro and animal studies to the human 
system. It also must be kept in mind that the 
composition and metabolic activities of 
intestinal flora of experimental animals are 
significantly different from those of humans. 
Indeed, it has been demonstrated that human 
intestinal microflora had different effects 
than mouse microflora concerning DNA 
adduct formation after exposure to mutagens 
(Hirayama et al.,2000).Further research is 
required to be done to identify the specific 
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strains and strain characteristics responsible 
for specific disease treatment, antitumor 
effects and the mechanisms by which these 
effects are mediated. However, even with 
the above reservations in mind and mindful 
of the limited number of human studies 
available, the use of probiotics for human 
disease management and cancer suppression 
is interesting, holds promise, and certainly 
deserves more scrutiny. Research works to 
identify which probiotic, prebiotic, or 
synbiotic will be most efficacious for a 
specific treatment should be a research focus 
for the future, the safety of their use for 
medical purpose and the safety concerns that 
may obstruct effective usage and thus 
judicious application of probiotics in disease 
management warrants serious investigations.  
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